Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Elo Mutual Pension Insurance Co

Elo Mutual Pension Insurance Co increased its position in Illumina, Inc. (NASDAQ:ILMN) by 10.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 15,581 shares of the life sciences company’s stock after acquiring an additional 1,431 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Illumina were worth $2,082,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Bank of Stockton grew its holdings in Illumina by 3.8% in the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after purchasing an additional 80 shares during the last quarter. Stephens Inc. AR grew its stake in Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares during the last quarter. Spire Wealth Management grew its stake in Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after acquiring an additional 97 shares during the last quarter. IFP Advisors Inc increased its holdings in Illumina by 19.1% during the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after acquiring an additional 99 shares in the last quarter. Finally, Brooklyn Investment Group raised its position in Illumina by 20.5% during the fourth quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock worth $82,000 after acquiring an additional 104 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ILMN shares. Stephens reissued an “overweight” rating and set a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Morgan Stanley reduced their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Trading Down 2.8 %

Shares of ILMN stock opened at $80.00 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $79.30 and a fifty-two week high of $156.66. The firm’s 50 day moving average price is $102.80 and its two-hundred day moving average price is $126.81. The stock has a market cap of $12.67 billion, a price-to-earnings ratio of -10.42, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.